C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin’s Lymphoma at the American Society of Hematology (ASH) Annual Meeting
C4 Therapeutics (Nasdaq: CCCC) announced the acceptance of two abstracts from their ongoing Phase 1/2 trial of cemsidomide for presentation at the ASH Annual Meeting in December 2024. The presentations will include Non-Hodgkin's lymphoma (NHL) data as an oral presentation and multiple myeloma (MM) data as a poster presentation. Both presentations will feature updated data compared to the abstracts on December 8th. The company will host an investor webcast at 2 PM PT following the presentations to discuss the results.
C4 Therapeutics (Nasdaq: CCCC) ha annunciato l'accettazione di due abstract provenienti dal loro in corso studio clinico di Fase 1/2 su cemsidomide per la presentazione all'Assemblea Annuale ASH nel dicembre 2024. Le presentazioni includeranno i dati sul linfoma non Hodgkin (NHL) come presentazione orale e i dati su mieloma multiplo (MM) come presentazione in poster. Entrambe le presentazioni presenteranno dati aggiornati rispetto agli abstract dell'8 dicembre. L'azienda organizzerà un webcast per gli investitori alle 14:00 PT dopo le presentazioni per discutere i risultati.
C4 Therapeutics (Nasdaq: CCCC) anunció la aceptación de dos resúmenes de su ensayo en curso de Fase 1/2 sobre cemsidomide para su presentación en la Reunión Anual de ASH en diciembre de 2024. Las presentaciones incluirán datos sobre linfoma no Hodgkin (NHL) como presentación oral y datos sobre mieloma múltiple (MM) como presentación en póster. Ambas presentaciones contarán con datos actualizados en comparación con los resúmenes del 8 de diciembre. La compañía llevará a cabo un webcast para inversores a las 2 PM PT tras las presentaciones para discutir los resultados.
C4 Therapeutics (Nasdaq: CCCC)는 2024년 12월 ASH 연례 회의에서 발표할 cemsidomide의 진행 중인 1/2상 시험에서 두 개의 초록이 수락되었다고 발표했습니다. 발표 내용에는 비호지킨 림프종(NHL) 데이터가 구두 발표로, 다발성 골수종(MM) 데이터가 포스터 발표로 포함됩니다. 두 발표 모두 12월 8일의 초록과 비교하여 업데이트된 데이터를 특징으로 합니다. 회사는 발표 후 오후 2시 PT에 투자자 웹캐스트를 개최하여 결과에 대해 논의할 예정입니다.
C4 Therapeutics (Nasdaq: CCCC) a annoncé l'acceptation de deux résumés de son essai en cours de Phase 1/2 sur cemsidomide pour présentation lors de la réunion annuelle de l'ASH en décembre 2024. Les présentations comprendront des données sur le lymphome non hodgkinien (NHL) en tant que présentation orale et des données sur le myélome multiple (MM) sous forme de poster. Les deux présentations présenteront des données mises à jour par rapport aux résumés du 8 décembre. L'entreprise organisera un webinaire pour les investisseurs à 14h00 PT après les présentations pour discuter des résultats.
C4 Therapeutics (Nasdaq: CCCC) gab die Annahme von zwei Abstracts aus ihrer laufenden Phase 1/2-Studie zu cemsidomide für die Präsentation auf dem ASH-Jahrestreffen im Dezember 2024 bekannt. Die Präsentationen beinhalten Daten zu non-Hodgkin-Lymphom (NHL) als mündliche Präsentation und Daten zu multiplem Myelom (MM) als Posterpräsentation. Beide Präsentationen werden aktualisierte Daten im Vergleich zu den Abstracts vom 8. Dezember enthalten. Das Unternehmen wird nach den Präsentationen um 14:00 Uhr PT ein Webcast für Investoren veranstalten, um die Ergebnisse zu besprechen.
- Phase 1/2 trial data selected for both oral and poster presentations at major medical conference (ASH)
- Multiple indications being pursued simultaneously (NHL and MM)
- None.
C4T to Host Webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET)
WATERTOWN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that two abstracts from the ongoing Phase 1/2 trial of cemsidomide have been accepted for presentation at the ASH Annual Meeting taking place from December 7 – 10, 2024 in San Diego, California. Non-Hodgkin’s lymphoma (NHL) data will be shared as an oral presentation and multiple myeloma (MM) data will be shared as a poster presentation. The abstracts are available online on the ASH Annual Meeting website.
The presentations on December 8th at the ASH Annual Meeting will include updated data compared to the abstracts.
NHL Oral Presentation Details:
Title: Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, in Patients with Non-Hodgkin’s Lymphoma
Format: Oral (10-minute presentation, followed by a 5-minute discussion)
Session: T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: When Old Meets New in T Cell Lymphomas
Session Date: Sunday, December 8, 2024
Presentation Time: 10:30 AM PT (1:30 PM ET)
Location: San Diego Convention Center, Ballroom 20CD
MM Poster Presentation Details:
Title: Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDAC® Degrader, with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
Format: Poster presentation
Session: Multiple Myeloma: Pharmacologic Therapies: Poster II
Session Date: Sunday, December 8, 2024
Presentation Time: 6:00 PM - 8:00 PM PT (9 PM – 11 PM ET)
Location: San Diego Convention Center, Halls G-H
Publication Number: 3366
C4T Investor Webcast
C4T will host a webcast on Sunday, December 8, 2024 at 2 PM PT (5 PM ET). A live webcast of the event will be available using this link or under the “Events & Presentations” page of the Investors section on the company’s website at www.c4therapeutics.com. A replay of the webcast will be archived and available following the event.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
About Cemsidomide
Cemsidomide is an orally bioavailable MonoDAC® degrader designed to be highly potent and selective against its intended targets of Ikaros (IKZF1) and Aiolos (IKZF3) and overcome shortcomings of currently approved therapies to treat multiple myeloma (MM) and non-Hodgkin’s lymphoma (NHL). Cemsidomide is currently in a Phase 1 dose escalation study in MM and NHL. Initial clinical data show cemsidomide is well-tolerated, demonstrates anti-myeloma activity and displays evidence of immunomodulatory effects. More information about this trial may be accessed at www.clinicaltrials.gov (identifier: NCT04756726).
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
When will C4 Therapeutics (CCCC) present cemsidomide trial data at ASH 2024?
What types of cancer is C4 Therapeutics (CCCC) studying with cemsidomide?
When is C4 Therapeutics (CCCC) hosting their investor webcast for the ASH 2024 data?
